NCT07473505 Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospective Case Series
| NCT ID | NCT07473505 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Reset Medical and Wellness Center |
| Condition | PTSD |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-03-20 |
| Primary Completion | 2027-02-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2026-03-20 with a primary completion date of 2027-02-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study prospectively evaluates the effects of Integrative Bilateral Cervical Sympathetic Block (BCSB) on trauma-related symptoms in Special Operations Veterans, comparing outcomes in those receiving BCSB alone versus BCSB combined with structured integrative therapy. Using standardized FDA-approved dosing, validated symptom measures, and strict safety criteria, the study aims to determine whether this dual-level autonomic intervention improves PTSD-related and TBI-related symptoms, and whether pairing the procedure with therapy enhances durability and overall clinical benefit.
Eligibility Criteria
Inclusion Criteria: * 18 years or older * PTSD (PCL Score of 33 or greater at baseline screening) * Willing and able to provide informed consent and complete study procedures * Fluent in English * Special Operations Forces Veteran Exclusion Criteria: * Recent Sympathetic Block: Receipt of any cervical sympathetic block (including stellate ganglion block \[SGB\], dual sympathetic ganglion block \[DSGB\], or bilateral SGB/BCSB), whether unilateral or bilateral, within the past 6 months. * Concurrent interventional clinical trial participation: Currently enrolled in another interventional clinical trial or receiving any experimental treatment targeting PTSD, TBI, or autonomic dysfunction during the study period * Acute Psychiatric Instability: Currently experiencing acute psychiatric crisis requiring inpatient care, active suicidal or homicidal intent, or untreated mania, psychosis, or severe dissociation * Medical Contraindications to BCSB: Any known anatomical abnormalities, bleeding disorders, allergy to local anesthetics, pregnancy, or comorbidities that represent a contraindication to receiving a cervical sympathetic block, per the treating physician's judgment. * Language or communication barriers: Inability to read, speak, or understand English sufficiently to complete informed consent and study assessments * Low PTSD Symptom Severity at Baseline: PCL-5 Score \< 33 at screening, indicating subclinical or minimal PTSD symptoms (Rationale: to ensure measurable clinical benefit and reduce floor effects)
Contact & Investigator
Michael Louwers, MD
PRINCIPAL INVESTIGATOR
Reset Medical and Wellness Center
Frequently Asked Questions
Who can join the NCT07473505 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07473505 currently recruiting?
Yes, NCT07473505 is actively recruiting participants. Contact the research team at mlouwers@theresetcenter.com for enrollment information.
Where is the NCT07473505 trial being conducted?
This trial is being conducted at Strongsville, United States.
Who is sponsoring the NCT07473505 clinical trial?
NCT07473505 is sponsored by Reset Medical and Wellness Center. The principal investigator is Michael Louwers, MD at Reset Medical and Wellness Center. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.